-
February 21, 2012
As expected, the European Commission has granted marketing authorisation for AstraZeneca's thyroid cancer pill Caprelsa
Full story
-
November 20, 2011
The latest set of opinions from the EMA has brought good news for AstraZeneca and Merck KGaA, while the safety of Boehringer Ingelheim's Pradaxa has been backed despite an increasing number of fatal cases of bleeding in patients treated with the anticoagulant.
Full story
-
August 02, 2011
AstraZeneca says that Axanum, a fixed-dose combination of low-dose aspirin and its antiulcerant blockbuster Nexium (esomeprazole), has received positive agreement for approval in 23 European Union member countries and in Norway
Full story
-
April 07, 2011
AstraZeneca has been boosted by the news that regulators in the USA have given the green light to vandetanib for a rare form of thyroid cancer.
Full story
-
January 10, 2011
AstraZeneca's vandetanib has suffered a setback in the USA after regulators said they need more time to assess the drug as a treatment for non-operable locally advanced or metastatic medullary thyroid cancer (MTC).
Full story
-
December 03, 2010
Advisors to the US Food and Drug Administration have backed the use of AstraZeneca's vandetanib to treat a rare type of thyroid cancer, although they are concerned about dosage
Full story
-
September 23, 2010
AstraZeneca has submitted vandetanib for the treatment of thyroid cancer to regulators on both sides of the Atlantic, having pulled a filing for lung cancer last year
Full story